Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here

Melody Hermel, Madison Lieberman, Leandro Slipczuk, Jamal S. Rana, Salim S. Virani

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)

Abstract

Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on monoclonal antibodies, gene silencing therapies, and gene editing techniques for the management of hyperlipidemia. The current era of cutting-edge pharmaceuticals targeting low density lipoprotein cholesterol, PCSK9, lipoprotein (a), angiopoietin-like 3, and apolipoprotein C3 are reviewed. We outline what is known, studies in progress, and futuristic goals. This review of available and upcoming biotechnological lipid therapies is presented for clinicians managing patients with familial hyperlipidemia, statin intolerance, hypertriglyceridemia, or elevated lipoprotein (a) levels.

Original languageEnglish
Article number459
JournalPharmaceutics
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 2023
Externally publishedYes

Keywords

  • atherosclerotic cardiovascular disease
  • cardiovascular prevention
  • hyperlipidemia
  • hypertriglyceridemia
  • lipoprotein (a)

Fingerprint

Dive into the research topics of 'Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here'. Together they form a unique fingerprint.

Cite this